Meeting
2017 ASCO Annual Meeting
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.
Authors
Hans-Georg Wirsching
Department of Neurology, University Hospital, Zürich, Switzerland
Hans-Georg Wirsching , Ghazaleh Tabatabai , Ulrich Roelcke , Andreas Felix Hottinger , Andrea Schmid , Ludwig Plasswilm , Katrin Lisa Conen , Thomas Hundsberger , Francesca Caparrotti , Roger Von Moos , Christian Alexander Riklin , Luca Remonda , Patrick Roth , Leonhard Held , Elisabeth Jane Rushing , Adrian Ochsenbein , Michael Weller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01443676
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2014)
DOI
10.1200/JCO.2017.35.15_suppl.2014
Abstract #
2014
Poster Bd #
256
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE).
First Author: Ghazaleh Tabatabai
Poster
2014 ASCO Annual Meeting
Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).
First Author: Shyam Kumar Tanguturi
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro
Poster
2019 ASCO Annual Meeting
Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.
First Author: Mitsuaki Shirahata